Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,667
  • Shares Outstanding, K 11,171
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,200 K
  • 60-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ANVS with:

Options Overview Details

View History
  • Implied Volatility 162.81% ( -60.35%)
  • Historical Volatility 194.49%
  • IV Percentile 1%
  • IV Rank 1.79%
  • IV High 472.50% on 12/13/23
  • IV Low 157.17% on 12/20/23
  • Put/Call Vol Ratio 0.89
  • Today's Volume 12,249
  • Volume Avg (30-Day) 5,851
  • Put/Call OI Ratio 2.10
  • Today's Open Interest 95,792
  • Open Int (30-Day) 88,305

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.70
  • Number of Estimates 2
  • High Estimate -0.55
  • Low Estimate -0.85
  • Prior Year -1.07
  • Growth Rate Est. (year over year) +34.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.53 +78.37%
on 07/02/24
12.51 -35.41%
on 07/02/24
+1.27 (+18.65%)
since 06/03/24
3-Month
4.53 +78.37%
on 07/02/24
20.00 -59.60%
on 04/29/24
-3.21 (-28.43%)
since 04/03/24
52-Week
4.53 +78.37%
on 07/02/24
22.49 -64.07%
on 12/27/23
-6.03 (-42.76%)
since 07/03/23

Most Recent Stories

More News
Annovis Bio (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.08 (-12.93%)
Annovis Bio (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for Alzheimer’s

June is Alzheimer’s & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer’s disease and other forms of dementia, as well as the importance of brain health. Even though the...

ANVS : 8.08 (-12.93%)
Annovis Bio (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.08 (-12.93%)
Annovis Bio (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is hosting...

ANVS : 8.08 (-12.93%)
Annovis Bio (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting...

ANVS : 8.08 (-12.93%)
Annovis Bio (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”),...

ANVS : 8.08 (-12.93%)
Annovis Bio (NYSE: ANVS) Is ‘One to Watch’

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease...

ANVS : 8.08 (-12.93%)
Annovis Bio (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.08 (-12.93%)
S&P Futures Tick Lower as Investors Await Key U.S. GDP Data and Fed Speak

March S&P 500 E-Mini futures (ESH24) are trending down -0.27% this morning as market participants looked ahead to a new round of U.S. economic data, comments from Fed officials, and earnings reports from...

ESH24 : 5,101.67s (-1.01%)
NCLH : 17.54 (-0.40%)
CEG : 210.07 (+1.90%)
ZM : 58.63 (+0.50%)
WDAY : 225.55 (-0.53%)
U : 15.73 (-1.75%)
CRM : 260.95 (+1.86%)
TJX : 110.39 (+0.17%)
SNOW : 142.86 (+0.66%)
HPQ : 34.85 (+0.14%)
ASM.NA : 703.200 (-0.65%)
RKT.LN : 4,231.000 (-0.63%)
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and...

ANVS : 8.08 (-12.93%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 10.95
2nd Resistance Point 10.09
1st Resistance Point 9.09
Last Price 8.08
1st Support Level 7.23
2nd Support Level 6.37
3rd Support Level 5.37

See More

52-Week High 22.49
Fibonacci 61.8% 15.63
Fibonacci 50% 13.51
Fibonacci 38.2% 11.39
Last Price 8.08
52-Week Low 4.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar